A clinically useful approach to enhance immunological memory and antitumor immunity

Alex Berezhnoy; Anugraha Rajagopalan; Eli Gilboa

doi:10.4161/onci.28811

A clinically useful approach to enhance immunological memory and antitumor immunity

Alex Berezhnoy, Anugraha Rajagopalan, Eli Gilboa

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Persistence of vaccine-induced immune responses, not the initial magnitude, best correlates with protective antitumor immunity. In mice, oligonucleotide aptamer-targeted siRNA inhibition of mammalian target of rapamycin (mTOR) activity in activated CD8+ T cells promotes their differentiation into functionally competent memory cells leading to enhanced antitumor immunity, a protective effect superior to that of non-targeted administration of the mTOR inhibitor rapamycin.

Original language	English (US)
Article number	e28811
Journal	OncoImmunology
Volume	3
Issue number	5
DOIs	https://doi.org/10.4161/onci.28811
State	Published - 2014

Keywords

4-1BB costimulation
Aptamers
MTOR
T cell memory
Tumor immunity

ASJC Scopus subject areas

Immunology and Allergy
Oncology
Immunology

Access to Document

10.4161/onci.28811

Fingerprint Dive into the research topics of 'A clinically useful approach to enhance immunological memory and antitumor immunity'. Together they form a unique fingerprint.

Cite this

@article{16bae78bbdd44473804a580973f157cd,

title = "A clinically useful approach to enhance immunological memory and antitumor immunity",

abstract = "Persistence of vaccine-induced immune responses, not the initial magnitude, best correlates with protective antitumor immunity. In mice, oligonucleotide aptamer-targeted siRNA inhibition of mammalian target of rapamycin (mTOR) activity in activated CD8+ T cells promotes their differentiation into functionally competent memory cells leading to enhanced antitumor immunity, a protective effect superior to that of non-targeted administration of the mTOR inhibitor rapamycin.",

keywords = "4-1BB costimulation, Aptamers, MTOR, T cell memory, Tumor immunity",

author = "Alex Berezhnoy and Anugraha Rajagopalan and Eli Gilboa",

year = "2014",

doi = "10.4161/onci.28811",

language = "English (US)",

volume = "3",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "5",

}

TY - JOUR

T1 - A clinically useful approach to enhance immunological memory and antitumor immunity

AU - Berezhnoy, Alex

AU - Rajagopalan, Anugraha

AU - Gilboa, Eli

PY - 2014

Y1 - 2014

N2 - Persistence of vaccine-induced immune responses, not the initial magnitude, best correlates with protective antitumor immunity. In mice, oligonucleotide aptamer-targeted siRNA inhibition of mammalian target of rapamycin (mTOR) activity in activated CD8+ T cells promotes their differentiation into functionally competent memory cells leading to enhanced antitumor immunity, a protective effect superior to that of non-targeted administration of the mTOR inhibitor rapamycin.

AB - Persistence of vaccine-induced immune responses, not the initial magnitude, best correlates with protective antitumor immunity. In mice, oligonucleotide aptamer-targeted siRNA inhibition of mammalian target of rapamycin (mTOR) activity in activated CD8+ T cells promotes their differentiation into functionally competent memory cells leading to enhanced antitumor immunity, a protective effect superior to that of non-targeted administration of the mTOR inhibitor rapamycin.

KW - 4-1BB costimulation

KW - Aptamers

KW - MTOR

KW - T cell memory

KW - Tumor immunity

UR - http://www.scopus.com/inward/record.url?scp=84904052381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904052381&partnerID=8YFLogxK

U2 - 10.4161/onci.28811

DO - 10.4161/onci.28811

M3 - Article

AN - SCOPUS:84904052381

VL - 3

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 5

M1 - e28811

ER -